The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pharmacokinetics and drug interactions of eslicarbazepine acetate
Abstract
Summary: Eslicarbazepine acetate (ESL) is a novel once‐daily antiepileptic drug (AED) approved in Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical program in adult patients with partial onset seizures previously not controlled with treatment with one to three AEDs, including carbamazepine (CBZ). ESL shares with CBZ and oxcarbazepine (OXC) the dibenzazepine nucleus bearing the 5‐carboxamide substitute, but is structurally different at the 10,11 position. This molecular variation results in differences in metabolism, preventing the formation of toxic epoxide metabolites such as carbamazepine‐10,11‐epoxide. Unlike OXC, which is metabolized to both eslicarbazepine and (R)‐licarbazepine, ESL is extensively converted to eslicarbazepine. The systemic exposure to eslicarbazepine after ESL oral administration is approximately 94% of the parent dose, with minimal exposure to (R)‐licarbazepine and OXC. After ESL oral administration, the effective half‐life (t 1/2,eff) of eslicarbazepine was 20–24 h, which is approximately two times longer than its terminal half‐life (t 1/2). At clinically relevant doses (400–1,600 mg/day) ESL has linear pharmacokinetics (PK) with no effects of gender or moderate liver impairment. However, because eslicarbazepine is eliminated primarily (66%) by renal excretion, dose adjustment is recommended for patients with renal impairment. Eslicarbazepine clearance is induced by phenobarbital, phenytoin, and CBZ and it dose‐dependently decreases plasma exposure of oral contraceptive and simvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430 · cited 1×
“In the past decade, a biopharmaceutic classification system (BCS) has been established to categorize drugs according to their water solubility and ability to pass across membranes (Amidon et al., 1995; Wu & Benet, 2005; Rowland & Tozer, 2010).”
BackgroundWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Effective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106
Cited by
Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments
Gambeta, E., Chichorro, J. G., & Zamponi, G. W. (2020) · Molecular Pain · doi:10.1177/1744806920901890 · Cited by 376
Gidal, B. E., Clark, A. M., Anders, B., & Gilliam, F. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.020 · Cited by 26
Grunze, H., Kotlik, E., Costa, R., Nunes, T., Falcão, A., Almeida, L., & Soares-da-Silva, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.013 · Cited by 22
Self-citationMomper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001270 · Cited by 3
Metadata
- Authors
- Bialer, M., & Soares‐da‐Silva, P.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2012-05-21
- Volume
- 53
- Issue
- 6
- Pages
- 935-946
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1530894628
- Cited by
- 168
- References
- 3
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and drug interactions of eslicarbazepine acetate. https://app.cochat.ai/papers/10.1111/j.1528-1167.2012.03519.x
- The paper
- Bialer, M., & Soares‐da‐Silva, P. (2012). Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. https://doi.org/10.1111/j.1528-1167.2012.03519.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.